Immune Pharmaceuticals Announces Presentation at The Liver Meeting 2017

Poster demonstrates activity of anti-eotaxin-1 antibodies in an animal model of immune-mediated hepatitis

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the results of a study investigating the therapeutic effect of oral and parenteral administration of anti-eotaxin-1 antibodies in an animal model of immune-mediated hepatitis will be presented at The Liver Meeting 2017 - the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place October 20-24, 2017 in Washington, DC.  Dr. Yaron Ilan, Professor of Medicine, and Director, Department of Medicine at Hebrew University's Hadassah Hospital in Jerusalem, Israel, and an Immune Pharmaceuticals collaborator, will present the data in a poster.

The poster (#350), entitled "Oral administration of anti-eotaxin-1 monoclonal antibody is biologically active in the gut and alleviates immune-mediated hepatitis: A novel personalized therapy for immune-associated liver diseases" (#350) will be presented Friday, October 20 between 12:00 and 1:30 PM ET at the "Autoimmune and Cholestatic Liver Disease" session. The study aimed to evaluate the biological activity and immunomodulatory effect of oral and parenteral administration of anti-eotaxin-1 antibodies in the concanavalin A (ConA) mouse model of immune hepatitis. Anti-eotaxin-1 antibodies, administered two hours prior to the induction of hepatitis, lowered eotaxin-1 levels and prevented the development of hepatitis compared to controls.

Dr. Ilan commented, "These experiments showed that blocking eotaxin-1 can have a profound impact on the development of hepatic inflammation. Anti-eotaxin-1 antibodies lowered eotaxin-1 levels and were effective at blocking liver injury whether administered parenterally or orally.  These results have obvious implications for the potential use of bertilimumab in liver diseases in which chronic inflammation plays a role, including NASH."

Elliot Maza, President and Chief Executive Officer of Immune Pharmaceuticals, stated, "Our collaboration with Dr. Ilan has been fruitful and yielded results suggesting that blocking eotaxin-1 can have a beneficial effect in liver diseases.  We will continue to explore the development of bertilimumab in liver diseases, further to our strategic business plan of focusing our resources on this first-in-class antibody."

Englewood Cliffs, NJ, October 11, 2017

For further information, contact: investors@immunepharma.com

About Immune Pharmaceuticals
Immune Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.  Our lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, we are conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other diseases, including NASH, atopic dermatitis, immune and inflammatory hepatitis, and asthma.

Safe Harbor Statements Regarding Forward Looking Statements
The statements in this news release made by representatives of Immune Pharmaceuticals, Inc. relating to matters that are not historical facts, including without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Immune's product candidates and the sufficiency of Immune's cash and other capital resources, the continued development by Immune of bertilimumab or its determination to seek Orphan Drug designation for the pharmaceutical product of bertilimumab are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Immune's ability to fund such efforts with or without partners. Immune undertakes no obligation to update any of these statements. In addition, there can be no assurance that the Company will ever successfully complete its anticipated corporate restructuring, or that the Company will be able to reduce expenses, capitalize on strategic alternatives, develop its assets, and generate value for shareholders. The Company may, at any time and for any reason until the proposed spin-off is complete, abandon the spin-off or modify its terms and conditions, or consider competing, alternate or complimentary transactions or offers by third parties at the discretion of Immune's board of directors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Immune's filings with the Securities and Exchange Commission, including those discussed in Immune's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q periodic reports filed on Form 8-K.

SOURCE Immune Pharmaceuticals Inc.


Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018

Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at the BIO CEO & Investor Conference, to be held February 12-13 at the New York Marriott Marquis in New York, NY.


Immune Pharmaceuticals Announces Adjournment of Annual Meeting

Annual Meeting to Resume Thursday, February 15, 2018


Immune Pharmaceuticals to Present at the NobleCon 14 Annual Investor Conference on January 30, 2018

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at NobleCon14- Noble Capital Markets' Fourteenth Annual Investor Conference, to be held January 29-30 at the W Hotel in Fort Lauderdale, Florida.


Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018

Oral Presentation to Include Positive Interim Results from its Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid


Immune Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference on January 10, 2018

Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that it will present at Biotech Showcase ™ 2018, to be held January 8-10 during the most important week in healthcare investment forums at the Hilton San Francisco Union Square.


Notice to attend the Annual General Meeting of Shareholders of Immune Pharmaceuticals

The shareholders of Immune Pharamceuticals, Inc. (First North: IMNP), (the "Company") are hereby convened to the 2017 Annual General Meeting (the "AGM") to be held on Thursday, 25 January 2018 at 4:00 PM Central European Time (CET) at the offices of Nixon Peabody LLP, 55 West 46th Street, New York, New York 10036. 


Immune Pharmaceuticals Announces Change in Certifying Accountant

Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the "Company") a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Audit Committee of the Company notified BDO USA, LLP ("BDO") the Company's independent registered public accounting firm for the fiscal year ending December 31, 2017, that the Company and its Audit Committee had determined to dismiss BDO effective as of December 7, 2017. On and effective as of December 7, 2017, the Company entered into an engagement letter with Marcum, LLP ("Marcum") as approved by the Audit Committee, and engaged Marcum to act as the Company's independent registered public accounting firm.


Immune Pharmaceuticals Announces 2017 Annual Shareholder Meeting

Englewood Cliffs, NJ, USA - December 13, 2017 - Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the "Company") a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that the Company filed a preliminary proxy statement with the United States Securities and Exchange Commission ("SEC") on December 8, 2017 in connection with the Company's 2017 Annual Meeting of Stockholders, which is proposed to be held on January 25, 2018. The SEC review period for filings of this type customarily are ten (10) calendar days, but may be longer in the discretion of the SEC. The formal Notice of Annual Meeting and a definitive proxy statement more fully describing the purposes of the Annual Meeting will be distributed to all stockholders later this month following completion of the SEC approval process.


Immune Pharmaceuticals Appoints John Zhang, MD, PhD as Vice President, Research and Development

 Englewood Cliffs, NJ, USA - December 11, 2017 - Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) (the "Company"), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has appointed John Zhang, MD, PhD to the position of Vice President, Research and Development. Dr. Zhang will have oversight of the non-clinical aspects of the Company's drug development programs, incuding all pre- clinical studies, and will provide support for the clinical, regulatory and manufacturing activities for the Company's core pipeline assets, bertilimumab and nano-cyclosporin. Dr. Zhang joins the Company from Tesaro, Inc., Boston, MA, where he served as Director, Clinical Sciences since April 2016, and Director, Toxicology and Safety Pharmacology from Sept 2012 to March 2016.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: